3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
2
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Gastrointestinal
1
Dermatologic
1
Conditions
Mesothelioma, Malignant
2
Pancreatic Neoplasms
1
Myelodysplastic Syndromes
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Interventions
pembrolizumab
1
bemcentinib
1
Tamoxifen
1
Radiotherapy
1
Quality of Life
1
Patient Reported Outcome Measures
1
PM 01183
1
Molecular Diagnostic Techniques
1
Irinotecan
1
Immunotherapy
1
Immunologic Techniques
1
Fentanyl
1
Erlotinib Hydrochloride
1
Drug Therapy
1
Doxorubicin
1
Cisplatin
1
Biological Therapy
1
Biological Factors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
bemcentinib
×
Other solid neoplasm
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts